Yingjiu Jiang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yingjiu Jiang has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Jiajie Leng
Department of Cardiothoracic Surgery, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China
7 shared publications - Letai Li
Department of Cardiothoracic Surgery, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China
6 shared publications - Hongtao Tie
Department of Cardiothoracic Surgery, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China
4 shared publications Jiajie Leng
Department of Cardiothoracic Surgery, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China
3 shared publicationsHaibing Xiong
Affiliation Department of Neurosurgery, Banan Hospital Affiliated to Chongqing Medical University, Chongqing, China
2 shared publicationsHaiyan Wang
West China School of Medicine, Sichuan University, Chengdu, Sichuan, China
2 shared publications
Latest Publications
- Open Access
- 9 November 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1948414
Preoperative hypothyroidism is associated with increased morbidity and mortality following cardiac surgery: a pooled analysis
Introduction: The association between hypothyroidism and prognosis following cardiac surgery remains poorly understood. This study evaluated the association of preoperative hypothyroidism with postoperative complications and mortality. Methods: PubMed, Embase, Cochrane Library, Web of Science, MEDLINE, and Scopus were searched from inception to December 17, 2025, to identify eligible studies. Pooled odds ratios and 95% confidence intervals were calculated to assess the associations between hypothyroidism and postoperative outcomes. Subgroup and leave-one-out sensitivity analyses explored heterogeneity and assessed the stability of the findings. Results: A total of 40,968 patients were enrolled in 22 studies for pooled analysis. For postoperative complications, more patients in the hypothyroid group developed acute kidney injury (OR = 2.61, 95% CI = 1.85 to 3.69, P = 0.00, I 2 = 0.00%), myocardial infarction (OR = 1.66, 95% CI = 1.23 to 2.23, P = 0.00, I 2 = 11.94%) and major adverse cardiovascular events (OR = 1.59, 95% CI = 1.45 to 1.74, P = 0.00, I 2 = 0.00%). However, regarding atrial fibrillation (OR = 1.24, 95% CI = 0.89 to 1.71, P = 0.20, I 2 = 71.05%), heart failure (OR = 1.46, 95% CI = 0.92 to 2.33, P = 0.11, I 2 = 0.00%), and stroke (OR = 1.36, 95% CI = 0.93 to 2.00, P = 0.11, I 2 = 0.00%), no statistically significant differences were observed between the two groups. As for mortality, both in-hospital mortality (OR = 1.70, 95% CI = 1.03 to 2.79, P = 0.04, I 2 = 0.00%) and long-term mortality (OR = 1.70, 95% CI = 1.29 to 2.25, P = 0.00, I 2 = 62.52%) were higher in the hypothyroid group. In additional analyses restricted to adjusted effect estimates, the association with heart failure reached statistical significance (aOR = 1.53, 95% CI = 1.14 to 2.04, P = 0.00, I 2 = 0.00%), whereas the associations with myocardial infarction and long-term mortality were not statistically significant. Conclusion: This study demonstrates that preoperative hypothyroidism was associated with several adverse outcomes following cardiac surgery, providing supportive evidence that surgeons should assess patients’ thyroid function and initiate appropriate interventions preoperatively.
- 9 November 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1948414
Open AccessPreoperative hypothyroidism is associated with increased morbidity and mortality following cardiac surgery: a pooled analysis
Introduction: The association between hypothyroidism and prognosis following cardiac surgery remains poorly understood. This study evaluated the association of preoperative hypothyroidism with postoperative complications and mortality. Methods: PubMed, Embase, Cochrane Library, Web of Science, MEDLINE, and Scopus were searched from inception to December 17, 2025, to identify eligible studies. Pooled odds ratios and 95% confidence intervals were calculated to assess the associations between hypothyroidism and postoperative outcomes. Subgroup and leave-one-out sensitivity analyses explored heterogeneity and assessed the stability of the findings. Results: A total of 40,968 patients were enrolled in 22 studies for pooled analysis. For postoperative complications, more patients in the hypothyroid group developed acute kidney injury (OR = 2.61, 95% CI = 1.85 to 3.69, P = 0.00, I 2 = 0.00%), myocardial infarction (OR = 1.66, 95% CI = 1.23 to 2.23, P = 0.00, I 2 = 11.94%) and major adverse cardiovascular events (OR = 1.59, 95% CI = 1.45 to 1.74, P = 0.00, I 2 = 0.00%). However, regarding atrial fibrillation (OR = 1.24, 95% CI = 0.89 to 1.71, P = 0.20, I 2 = 71.05%), heart failure (OR = 1.46, 95% CI = 0.92 to 2.33, P = 0.11, I 2 = 0.00%), and stroke (OR = 1.36, 95% CI = 0.93 to 2.00, P = 0.11, I 2 = 0.00%), no statistically significant differences were observed between the two groups. As for mortality, both in-hospital mortality (OR = 1.70, 95% CI = 1.03 to 2.79, P = 0.04, I 2 = 0.00%) and long-term mortality (OR = 1.70, 95% CI = 1.29 to 2.25, P = 0.00, I 2 = 62.52%) were higher in the hypothyroid group. In additional analyses restricted to adjusted effect estimates, the association with heart failure reached statistical significance (aOR = 1.53, 95% CI = 1.14 to 2.04, P = 0.00, I 2 = 0.00%), whereas the associations with myocardial infarction and long-term mortality were not statistically significant. Conclusion: This study demonstrates that preoperative hypothyroidism was associated with several adverse outcomes following cardiac surgery, providing supportive evidence that surgeons should assess patients’ thyroid function and initiate appropriate interventions preoperatively.
- 19 April 2026
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 146, 103138
Perioperative strategies for resectable EGFR-Mutant NSCLC: evidence hierarchy and clinical decision-making
- 19 April 2026
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 146, 103138
Perioperative strategies for resectable EGFR-Mutant NSCLC: evidence hierarchy and clinical decision-making
- Open Access
- 1 December 2025
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 17 (12) , 10897-10907
Impact of bronchial anastomosis wrapping on outcomes following sleeve lobectomy
Background: Sleeve lobectomy is widely used for the treatment of centrally located non-small cell lung cancer (NSCLC), aiming to preserve lung function while achieving complete tumor resection. Reinforcement of the bronchial anastomosis with autologous tissues, such as pericardium, has been proposed to reduce postoperative complications. However, the clinical necessity and prognostic significance of this technique remain controversial. This study aimed to evaluate whether wrapping of the bronchial anastomosis with autologous pericardium influences perioperative complications and long-term survival in patients undergoing sleeve lobectomy, thereby providing evidence for optimizing surgical decision-making and individualized management strategies. Methods: In this retrospective study, 91 patients with NSCLC who underwent sleeve lobectomy were included between 2012 and 2017. Group A (29 patients) did not undergo wrapping and group B (62 patients) underwent bronchial wrapping. After propensity score matching, 20 patients were included in each group. Overall survival (OS) was estimated using the Kaplan-Meier method and compared using the Log-rank test. Results: Wrapping of the bronchial anastomosis did not improve the 30- and 90-day mortality (3.45% and 3.45% vs. 9.68% and 12.9%, P=0.54 and P=0.30, respectively, before matching; 5% and 5% vs. 5% and 5%; P>0.99 and P>0.99, after matching), and there was no significant difference in 5-year OS (55.17% vs. 48.39%, P=0.79, before matching; 60% vs. 65%, P=0.58, after matching) between the two groups. Conclusions: This study concludes no evidence that bronchial anastomotic wrapping improves either short-term or long-term outcomes. Therefore, routine wrapping is not recommended; however, an individualized surgical strategy based on patient selection should still be considered.
- 1 December 2025
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 17 (12) , 10897-10907
Open AccessImpact of bronchial anastomosis wrapping on outcomes following sleeve lobectomy
Background: Sleeve lobectomy is widely used for the treatment of centrally located non-small cell lung cancer (NSCLC), aiming to preserve lung function while achieving complete tumor resection. Reinforcement of the bronchial anastomosis with autologous tissues, such as pericardium, has been proposed to reduce postoperative complications. However, the clinical necessity and prognostic significance of this technique remain controversial. This study aimed to evaluate whether wrapping of the bronchial anastomosis with autologous pericardium influences perioperative complications and long-term survival in patients undergoing sleeve lobectomy, thereby providing evidence for optimizing surgical decision-making and individualized management strategies. Methods: In this retrospective study, 91 patients with NSCLC who underwent sleeve lobectomy were included between 2012 and 2017. Group A (29 patients) did not undergo wrapping and group B (62 patients) underwent bronchial wrapping. After propensity score matching, 20 patients were included in each group. Overall survival (OS) was estimated using the Kaplan-Meier method and compared using the Log-rank test. Results: Wrapping of the bronchial anastomosis did not improve the 30- and 90-day mortality (3.45% and 3.45% vs. 9.68% and 12.9%, P=0.54 and P=0.30, respectively, before matching; 5% and 5% vs. 5% and 5%; P>0.99 and P>0.99, after matching), and there was no significant difference in 5-year OS (55.17% vs. 48.39%, P=0.79, before matching; 60% vs. 65%, P=0.58, after matching) between the two groups. Conclusions: This study concludes no evidence that bronchial anastomotic wrapping improves either short-term or long-term outcomes. Therefore, routine wrapping is not recommended; however, an individualized surgical strategy based on patient selection should still be considered.
- Open Access
- 18 November 2025
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 13, 1700855
Global burden of pulmonary arterial hypertension and health inequality in women of childbearing age from 1990 to 2021, with projections up to 2040: the global burden of disease 2021 study
Objective: To assess the global burden, trends, and inequalities of pulmonary arterial hypertension (PAH) among women of childbearing age (WCBA) from 1990 to 2021, projecting future trends to 2040. Methods: Using Global Burden of Disease (GBD) 2021 data, we analyzed PAH mortality, incidence, prevalence, and disability-adjusted life years (DALYs) among WCBA aged 15 to 49. Trends were assessed via age-standardized rates (ASR), estimated annual percentage change (EAPC), joinpoint regression, decomposition, and inequality analyses. Future burden was projected using Bayesian age-period-cohort, auto-regressive moving average, and exponential smoothing models. Results: The absolute number of PAH cases among WCBA increased globally from 1990 to 2021. Critically, the global age-standardized incidence rate (ASIR) showed a neglected upward trend (EAPC = 0.12), while mortality and DALY rates declined. Significant inequalities were observed, with the ASIR highest in low-middle SDI regions and prevalence highest in high SDI regions. Decomposition analysis identified population growth as the primary driver of increasing burden in low-resource settings. Projections indicate a continued rise in incidence by 2040, alongside declining mortality. Conclusion: This study demonstrated a persistent and growing PAH burden among WCBA, marked by significant inequalities. The rising incidence, particularly in low-resource settings, coupled with the cumulative prevalence in high-income regions, underscores an urgent need for targeted public health actions. Region-specific interventions are vital, including integrating PAH screening into maternal health programs in resource-poor settings and optimizing long-term management in high-income countries.
- 18 November 2025
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 13, 1700855
Open AccessGlobal burden of pulmonary arterial hypertension and health inequality in women of childbearing age from 1990 to 2021, with projections up to 2040: the global burden of disease 2021 study
Objective: To assess the global burden, trends, and inequalities of pulmonary arterial hypertension (PAH) among women of childbearing age (WCBA) from 1990 to 2021, projecting future trends to 2040. Methods: Using Global Burden of Disease (GBD) 2021 data, we analyzed PAH mortality, incidence, prevalence, and disability-adjusted life years (DALYs) among WCBA aged 15 to 49. Trends were assessed via age-standardized rates (ASR), estimated annual percentage change (EAPC), joinpoint regression, decomposition, and inequality analyses. Future burden was projected using Bayesian age-period-cohort, auto-regressive moving average, and exponential smoothing models. Results: The absolute number of PAH cases among WCBA increased globally from 1990 to 2021. Critically, the global age-standardized incidence rate (ASIR) showed a neglected upward trend (EAPC = 0.12), while mortality and DALY rates declined. Significant inequalities were observed, with the ASIR highest in low-middle SDI regions and prevalence highest in high SDI regions. Decomposition analysis identified population growth as the primary driver of increasing burden in low-resource settings. Projections indicate a continued rise in incidence by 2040, alongside declining mortality. Conclusion: This study demonstrated a persistent and growing PAH burden among WCBA, marked by significant inequalities. The rising incidence, particularly in low-resource settings, coupled with the cumulative prevalence in high-income regions, underscores an urgent need for targeted public health actions. Region-specific interventions are vital, including integrating PAH screening into maternal health programs in resource-poor settings and optimizing long-term management in high-income countries.
- 6 November 2025
- Published by Springer Nature in Inflammation Research
- Vol. 74 (1) , 1-22
PGC1α alleviates M1 macrophage polarization through dual regulation of succinate metabolism and TRAF5 expression to mitigate TLR4/NF-κB-driven inflammatory cascades and myocardial ischemia/reperfusion injury
Objective This study investigates the dual regulatory role of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α) in macrophage polarization and its therapeutic potential for mitigating myocardial ischemia/reperfusion injury (MI/RI). Methods By integrating in vivo murine myocardial MI/RI models with macrophage-specific genetic manipulation and multi-omics analyses, including transcriptomics, proteomics, and energy metabolomics, we comprehensively investigated the cardio-protective effects, immune regulation, and potential mechanism of PGC1α. Mechanistic validations were performed using macrophage hypoxia/reoxygenation models combined with gain- and loss-of-function experiments to elucidate the molecular interactions within the PGC1α-mediated signaling network. Results PGC1α emerged as a potential regulator of macrophage polarization through coordinated metabolic and protein regulation in MI/RI. It suppresses TLR4/NF-κB-driven inflammation via two prominent parallel pathways: (1) Metabolic control through SUCLG1/succinyl-CoA synthetase-mediated succinate generation; (2) negatively regulates protein by TRAF5 mRNA expression inhibition. This dual-axis regulation effectively dampens M1 macrophage polarization and pro-inflammatory cytokine storms. Furthermore, macrophage-specific PGC1α activation demonstrated cardio-protective effects by preserving cardiac function and reducing cardiomyocyte apoptosis. Conclusion Our findings established PGC1α as a potential regulator of macrophage polarization in MI/RI, bridging mitochondrial energy metabolism and protein expression with immune responses. The PGC1α-SUCLG1/succinate axis and PGC1α-TRAF5 axis unveil therapeutic targets and potential mechanisms for modulating inflammation in MI/RI. Future studies should focus on translating these mechanisms into clinical interventions through pharmacological PGC1α activation.
- 6 November 2025
- Published by Springer Nature in Inflammation Research
- Vol. 74 (1) , 1-22
PGC1α alleviates M1 macrophage polarization through dual regulation of succinate metabolism and TRAF5 expression to mitigate TLR4/NF-κB-driven inflammatory cascades and myocardial ischemia/reperfusion injury
Objective This study investigates the dual regulatory role of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α) in macrophage polarization and its therapeutic potential for mitigating myocardial ischemia/reperfusion injury (MI/RI). Methods By integrating in vivo murine myocardial MI/RI models with macrophage-specific genetic manipulation and multi-omics analyses, including transcriptomics, proteomics, and energy metabolomics, we comprehensively investigated the cardio-protective effects, immune regulation, and potential mechanism of PGC1α. Mechanistic validations were performed using macrophage hypoxia/reoxygenation models combined with gain- and loss-of-function experiments to elucidate the molecular interactions within the PGC1α-mediated signaling network. Results PGC1α emerged as a potential regulator of macrophage polarization through coordinated metabolic and protein regulation in MI/RI. It suppresses TLR4/NF-κB-driven inflammation via two prominent parallel pathways: (1) Metabolic control through SUCLG1/succinyl-CoA synthetase-mediated succinate generation; (2) negatively regulates protein by TRAF5 mRNA expression inhibition. This dual-axis regulation effectively dampens M1 macrophage polarization and pro-inflammatory cytokine storms. Furthermore, macrophage-specific PGC1α activation demonstrated cardio-protective effects by preserving cardiac function and reducing cardiomyocyte apoptosis. Conclusion Our findings established PGC1α as a potential regulator of macrophage polarization in MI/RI, bridging mitochondrial energy metabolism and protein expression with immune responses. The PGC1α-SUCLG1/succinate axis and PGC1α-TRAF5 axis unveil therapeutic targets and potential mechanisms for modulating inflammation in MI/RI. Future studies should focus on translating these mechanisms into clinical interventions through pharmacological PGC1α activation.
- Open Access
- 30 October 2025
- Published by Springer Nature in European Journal of Medical Research
- Vol. 30 (1) , 1-20
The global burden and trends of esophageal cancer caused by smoking among men from 1990 to 2021 and projections to 2040: An analysis of the Global Burden of Disease 2021
Esophageal cancer (EC) ranks 7th globally in cancer mortality, with smoking being a major preventable risk factor, particularly for squamous cell carcinoma predominant in Asia. This study quantifies the global burden of smoking-attributable EC among males using 2021 Global Burden of Disease data (1990–2021) and projects trends to 2040. Data on deaths and Disability-Adjusted Life Years (DALYs) for global burden of smoking-attributable EC among males were derived from the Global Burden of Diseases (GBD) Study 2021, along with the corresponding 95% uncertainty intervals (UIs). We analyzed with Joinpoint regression, age-period-cohort modeling for risk stratification, decomposition analysis, and Bayesian prediction. Global smoking-attributable EC deaths and DALYs among males decreased, concentrated in middle-to-high SDI regions. Age-standardized DALY rates (ASDR) declined significantly, with sharpest reductions in medium-SDI regions. East Asia bore disproportionate burden in China and Mongolia. Critical inflection occurred in 2004 by joinpoint and age-period-cohort analysis from 1990 to 2021. Mortality peak at 80–90 years and disability peak at 60–80 years. Decomposition analysis showed population growth and aging increased burden, offset by epidemiological improvements. Predictive analysis indicated stable-to-declining ASRs through 2040, contingent on sustained tobacco control in high-risk regions. The analysis indicated a global downward trend in EC attributable to smoking among males. While absolute burdens rise due to demographic pressures, declining ASRs reflect tobacco control progress. The 2004 inflection underscores policy impact, and East Asia's outsized burden necessitates targeted interventions. Our research underscores the profound influence of high BMI on EC attributable to smoking among males and provides a research foundation for future public health decision-making.
- 30 October 2025
- Published by Springer Nature in European Journal of Medical Research
- Vol. 30 (1) , 1-20
Open AccessThe global burden and trends of esophageal cancer caused by smoking among men from 1990 to 2021 and projections to 2040: An analysis of the Global Burden of Disease 2021
Esophageal cancer (EC) ranks 7th globally in cancer mortality, with smoking being a major preventable risk factor, particularly for squamous cell carcinoma predominant in Asia. This study quantifies the global burden of smoking-attributable EC among males using 2021 Global Burden of Disease data (1990–2021) and projects trends to 2040. Data on deaths and Disability-Adjusted Life Years (DALYs) for global burden of smoking-attributable EC among males were derived from the Global Burden of Diseases (GBD) Study 2021, along with the corresponding 95% uncertainty intervals (UIs). We analyzed with Joinpoint regression, age-period-cohort modeling for risk stratification, decomposition analysis, and Bayesian prediction. Global smoking-attributable EC deaths and DALYs among males decreased, concentrated in middle-to-high SDI regions. Age-standardized DALY rates (ASDR) declined significantly, with sharpest reductions in medium-SDI regions. East Asia bore disproportionate burden in China and Mongolia. Critical inflection occurred in 2004 by joinpoint and age-period-cohort analysis from 1990 to 2021. Mortality peak at 80–90 years and disability peak at 60–80 years. Decomposition analysis showed population growth and aging increased burden, offset by epidemiological improvements. Predictive analysis indicated stable-to-declining ASRs through 2040, contingent on sustained tobacco control in high-risk regions. The analysis indicated a global downward trend in EC attributable to smoking among males. While absolute burdens rise due to demographic pressures, declining ASRs reflect tobacco control progress. The 2004 inflection underscores policy impact, and East Asia's outsized burden necessitates targeted interventions. Our research underscores the profound influence of high BMI on EC attributable to smoking among males and provides a research foundation for future public health decision-making.
- Open Access
- 29 July 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (7) , e0327831
The global, regional and national burden of pancreatitis due to alcohol use: Results from the Global Burden of Disease Study 2021 and projections to 2040
Background: Alcohol use is a major risk factor for pancreatitis and global mortality. Despite its impact, comprehensive analyses of the burden across regions and sociodemographic strata remain scarce. This study examines global trends (1990–2021) and projects future burdens to 2040. Method: Data on Deaths and Disability-Adjusted Life Years (DALYs) attributable to alcohol-induced pancreatitis were retrieved from the 2021 iteration of the Global Burden of Diseases (GBD) database. Trends were analyzed, Age-Period-Cohort models quantified age, period, and cohort effects on Age-Standardized Mortality Rate (ASMR) and Age-Standardized Disability-Adjusted Life Year (ASDR). Associations with SDI were evaluated, burden decomposition applied, and projections made to 2040. Results: Globally, both age-standardized death rate (ASDR) and mortality ratio (ASMR) exhibited overall declines (EAPC for ASDR: −0.32%; ASMR: −0.27%), but the reduction was significantly smaller in males (ASDR-EAPC: −0.18%) compared to females (−1.34%). Notablly,Eastern Europe had the highest burden (ASDR: 64.03), High-income Asia-Pacific saw the largest declines (EAPC for ASDR: −2.45%; EAPC for ASMR: −2.96%), while Southeast Asia experienced the fastest increase (EAPC for ASDR: 1.98%; EAPC for ASMR: 2.13%). ASDR peaked at ages 45–49, with high-middle SDI countries showing the highest values. Period and cohort effects varied by SDI, with downward trends in high SDI countries and upward trends in lower SDI groups. Population growth and aging drove increases in deaths and DALYs, while epidemiologic changes reduced them. By 2040, deaths and DALYs will stabilize, ASMR will decline until 2034 then rise, and ASDR will decrease until 2035 then increase, driven by population growth. Conclusion: Alcohol-related pancreatitis burden demonstrates striking gender, age, and geographic heterogeneity. Targeted policies for high-risk groups (middle-aged/elderly males) and regions (Eastern Europe, Low-middle SDI countries), coupled with preparedness for aging-related burden escalation, are urgently needed.
- 29 July 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (7) , e0327831
Open AccessThe global, regional and national burden of pancreatitis due to alcohol use: Results from the Global Burden of Disease Study 2021 and projections to 2040
Background: Alcohol use is a major risk factor for pancreatitis and global mortality. Despite its impact, comprehensive analyses of the burden across regions and sociodemographic strata remain scarce. This study examines global trends (1990–2021) and projects future burdens to 2040. Method: Data on Deaths and Disability-Adjusted Life Years (DALYs) attributable to alcohol-induced pancreatitis were retrieved from the 2021 iteration of the Global Burden of Diseases (GBD) database. Trends were analyzed, Age-Period-Cohort models quantified age, period, and cohort effects on Age-Standardized Mortality Rate (ASMR) and Age-Standardized Disability-Adjusted Life Year (ASDR). Associations with SDI were evaluated, burden decomposition applied, and projections made to 2040. Results: Globally, both age-standardized death rate (ASDR) and mortality ratio (ASMR) exhibited overall declines (EAPC for ASDR: −0.32%; ASMR: −0.27%), but the reduction was significantly smaller in males (ASDR-EAPC: −0.18%) compared to females (−1.34%). Notablly,Eastern Europe had the highest burden (ASDR: 64.03), High-income Asia-Pacific saw the largest declines (EAPC for ASDR: −2.45%; EAPC for ASMR: −2.96%), while Southeast Asia experienced the fastest increase (EAPC for ASDR: 1.98%; EAPC for ASMR: 2.13%). ASDR peaked at ages 45–49, with high-middle SDI countries showing the highest values. Period and cohort effects varied by SDI, with downward trends in high SDI countries and upward trends in lower SDI groups. Population growth and aging drove increases in deaths and DALYs, while epidemiologic changes reduced them. By 2040, deaths and DALYs will stabilize, ASMR will decline until 2034 then rise, and ASDR will decrease until 2035 then increase, driven by population growth. Conclusion: Alcohol-related pancreatitis burden demonstrates striking gender, age, and geographic heterogeneity. Targeted policies for high-risk groups (middle-aged/elderly males) and regions (Eastern Europe, Low-middle SDI countries), coupled with preparedness for aging-related burden escalation, are urgently needed.
- 22 July 2025
- Published by Springer Nature in Surgical Endoscopy
- Vol. 39 (9) , 5811-5819
Enhanced recovery after surgery programs versus conventional rehabilitation for patients undergoing thoracoscopic radical resection of lung cancer in local regional hospitals: a prospective randomized controlled trial
Background An appropriate rehabilitation program should follow thoracoscopic lung cancer radical surgery (TLCRS) to promote patient recovery during the perioperative period. However, enhanced recovery after surgery (ERAS) and conventional rehabilitation mode (CRM) programs remain a subject of debate to date. Therefore, in this randomized controlled trial, we compared the effectiveness and safety of an ERAS program with those of a CRM program after TLCRS in local regional hospitals. Methods From August 2021 to July 2022, in this double-blind randomized controlled trial, 80 patients who met the inclusion criteria were randomly divided into two groups at a 1:1 ratio: the ERAS program and the CRM program. The primary outcomes were the effectiveness and socioeconomic effects of the two kinds of programs. The secondary outcomes included the incidence of postoperative complications and the safety of the two kinds of programs. Results Compared with the CRM group, the ERAS group experienced notable benefits (P < 0.001) in terms of length of hospital stay, postoperative length of hospital stay, time to thoracic drainage tube removal, time to postoperative oral feeding, time to postoperative ambulation, postoperative pain score, and hospitalization costs. Compared with the ERAS group, the CRM group experienced notable consequences such as postoperative atelectasis/pulmonary infections (P = 0.029) and prolonged operative times (P < 0.001). The incidence of postoperative ICU admission in the ERAS group was significantly lower than that in the CRM group (P = 0.048); however, the ERAS group had a higher rate of postoperative chest tube replacement than the CRM group did (P = 0.025). Conclusions Compared with the CRM program, the ERAS program is associated with a lower incidence of postoperative pulmonary complications, faster recovery, less pain, and smaller economic burden, improving patients’ postoperative prognoses.
- 22 July 2025
- Published by Springer Nature in Surgical Endoscopy
- Vol. 39 (9) , 5811-5819
Enhanced recovery after surgery programs versus conventional rehabilitation for patients undergoing thoracoscopic radical resection of lung cancer in local regional hospitals: a prospective randomized controlled trial
Background An appropriate rehabilitation program should follow thoracoscopic lung cancer radical surgery (TLCRS) to promote patient recovery during the perioperative period. However, enhanced recovery after surgery (ERAS) and conventional rehabilitation mode (CRM) programs remain a subject of debate to date. Therefore, in this randomized controlled trial, we compared the effectiveness and safety of an ERAS program with those of a CRM program after TLCRS in local regional hospitals. Methods From August 2021 to July 2022, in this double-blind randomized controlled trial, 80 patients who met the inclusion criteria were randomly divided into two groups at a 1:1 ratio: the ERAS program and the CRM program. The primary outcomes were the effectiveness and socioeconomic effects of the two kinds of programs. The secondary outcomes included the incidence of postoperative complications and the safety of the two kinds of programs. Results Compared with the CRM group, the ERAS group experienced notable benefits (P < 0.001) in terms of length of hospital stay, postoperative length of hospital stay, time to thoracic drainage tube removal, time to postoperative oral feeding, time to postoperative ambulation, postoperative pain score, and hospitalization costs. Compared with the ERAS group, the CRM group experienced notable consequences such as postoperative atelectasis/pulmonary infections (P = 0.029) and prolonged operative times (P < 0.001). The incidence of postoperative ICU admission in the ERAS group was significantly lower than that in the CRM group (P = 0.048); however, the ERAS group had a higher rate of postoperative chest tube replacement than the CRM group did (P = 0.025). Conclusions Compared with the CRM program, the ERAS program is associated with a lower incidence of postoperative pulmonary complications, faster recovery, less pain, and smaller economic burden, improving patients’ postoperative prognoses.
- Open Access
- 11 July 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (28) , e43040
Potential of vitamin D for the prevention of 3 types of cerebrovascular diseases: A 2-sample Mendelian randomization study
While nutritional and dietary interventions play a critical role in stroke prevention, the specific contributions of micronutrients remain incompletely understood. Observational studies suggest a potential association between vitamin D levels and cerebrovascular risk, but the causal role of vitamin D in distinct stroke subtypes – subarachnoid hemorrhage (SAH), intracerebral hemorrhage (ICH), and ischemic stroke (IS) – remains underexplored. Instrumental variables for vitamin D levels and stroke outcomes were derived from genome-wide association studies in the IEU Open genome-wide association studies database. A 2-sample Mendelian randomization (MR) framework was implemented to assess causal effects of vitamin D on SAH, ICH, and IS. The inverse variance weighted (IVW) method served as the primary analysis, supplemented by secondary analyses including weighted median, MR-Egger, and sensitivity assessments for pleiotropy (Cochran’ s Q-test, MR-PRESSO, MR-Egger intercept) and heterogeneity (leave-one-out analysis). Genetically predicted higher vitamin D levels demonstrated significant inverse associations with ICH risk (IVW odds ratio = 0.704, 95% CI: 0.584–0.904, P = .006) and IS risk (IVW odds ratio = 0.919, 95% CI: 0.849–0.995, P = .036), whereas no causal relationship was observed for SAH (IVW P = .091). Sensitivity analyses revealed no evidence of horizontal pleiotropy or influential outliers. This MR study provides novel genetic evidence supporting vitamin D as a protective factor against ICH and IS. Our findings highlight the potential clinical utility of vitamin D supplementation for cerebrovascular disease prevention, particularly in high-risk populations. Further investigations are warranted to elucidate biological mechanisms and validate these associations in diverse cohorts.
- 11 July 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (28) , e43040
Open AccessPotential of vitamin D for the prevention of 3 types of cerebrovascular diseases: A 2-sample Mendelian randomization study
While nutritional and dietary interventions play a critical role in stroke prevention, the specific contributions of micronutrients remain incompletely understood. Observational studies suggest a potential association between vitamin D levels and cerebrovascular risk, but the causal role of vitamin D in distinct stroke subtypes – subarachnoid hemorrhage (SAH), intracerebral hemorrhage (ICH), and ischemic stroke (IS) – remains underexplored. Instrumental variables for vitamin D levels and stroke outcomes were derived from genome-wide association studies in the IEU Open genome-wide association studies database. A 2-sample Mendelian randomization (MR) framework was implemented to assess causal effects of vitamin D on SAH, ICH, and IS. The inverse variance weighted (IVW) method served as the primary analysis, supplemented by secondary analyses including weighted median, MR-Egger, and sensitivity assessments for pleiotropy (Cochran’ s Q-test, MR-PRESSO, MR-Egger intercept) and heterogeneity (leave-one-out analysis). Genetically predicted higher vitamin D levels demonstrated significant inverse associations with ICH risk (IVW odds ratio = 0.704, 95% CI: 0.584–0.904, P = .006) and IS risk (IVW odds ratio = 0.919, 95% CI: 0.849–0.995, P = .036), whereas no causal relationship was observed for SAH (IVW P = .091). Sensitivity analyses revealed no evidence of horizontal pleiotropy or influential outliers. This MR study provides novel genetic evidence supporting vitamin D as a protective factor against ICH and IS. Our findings highlight the potential clinical utility of vitamin D supplementation for cerebrovascular disease prevention, particularly in high-risk populations. Further investigations are warranted to elucidate biological mechanisms and validate these associations in diverse cohorts.
- Open Access
- 9 May 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (19) , e42352
Association of omega-3/6 polyunsaturated fatty acids with three cerebrovascular diseases: A Mendelian randomization study
Nutritional and dietary interventions are important in the prevention of stroke, but many of the factors influencing stroke remain undefined. Although omega-3/6 polyunsaturated fatty acids (PUFAs) have been suggested to be associated with cerebrovascular diseases, studies on this topic are lacking. This study extracted and screened independent single nucleotide polymorphisms of omega-3/6 PUFAs and 3 types of cerebrovascular diseases data from the IEU Open GWAS database. A two-sample Mendelian randomization (MR) was used to examine the association between omega-3/6 PUFAs with subarachnoid hemorrhage (SAH), intracerebral hemorrhage (ICH), and ischemic stroke (IS). The primary analysis method was the inverse variance weighting method, supplemented by the weighted median and MR-Egger methods. Sensitivity and multiplicity were assessed using Cochran Q test, MR-PRESSO, MR-Egger regression, and leave-one-out analysis. This study was conducted in full compliance with the STROBE guidelines throughout. The inverse variance weighting analysis revealed a negative correlation between omega-3 PUFAs and SAH ( P = .0078). However, there was no correlation between omega-3 PUFAs and ICH ( P = .3930) and IS ( P = .2922). Additionally, there was no association between omega-6 PUFAs and SAH ( P = .1399), ICH ( P = .1399, 0.0660), and IS ( P = .8571) using all 3 analytical methods. No heterogeneity or horizontal pleiotropy was observed. The study suggested that omega-3 PUFAs had a significant protective role in SAH. However, omega-3/6 PUFAs were not found to be associated with other types of cerebrovascular diseases.
- 9 May 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (19) , e42352
Open AccessAssociation of omega-3/6 polyunsaturated fatty acids with three cerebrovascular diseases: A Mendelian randomization study
Nutritional and dietary interventions are important in the prevention of stroke, but many of the factors influencing stroke remain undefined. Although omega-3/6 polyunsaturated fatty acids (PUFAs) have been suggested to be associated with cerebrovascular diseases, studies on this topic are lacking. This study extracted and screened independent single nucleotide polymorphisms of omega-3/6 PUFAs and 3 types of cerebrovascular diseases data from the IEU Open GWAS database. A two-sample Mendelian randomization (MR) was used to examine the association between omega-3/6 PUFAs with subarachnoid hemorrhage (SAH), intracerebral hemorrhage (ICH), and ischemic stroke (IS). The primary analysis method was the inverse variance weighting method, supplemented by the weighted median and MR-Egger methods. Sensitivity and multiplicity were assessed using Cochran Q test, MR-PRESSO, MR-Egger regression, and leave-one-out analysis. This study was conducted in full compliance with the STROBE guidelines throughout. The inverse variance weighting analysis revealed a negative correlation between omega-3 PUFAs and SAH ( P = .0078). However, there was no correlation between omega-3 PUFAs and ICH ( P = .3930) and IS ( P = .2922). Additionally, there was no association between omega-6 PUFAs and SAH ( P = .1399), ICH ( P = .1399, 0.0660), and IS ( P = .8571) using all 3 analytical methods. No heterogeneity or horizontal pleiotropy was observed. The study suggested that omega-3 PUFAs had a significant protective role in SAH. However, omega-3/6 PUFAs were not found to be associated with other types of cerebrovascular diseases.